<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35595733</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficient capture of circulating tumor cells with low molecular weight folate receptor-specific ligands.</ArticleTitle>
        <Pagination>
          <StartPage>8555</StartPage>
          <MedlinePgn>8555</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">8555</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-12118-3</ELocationID>
        <Abstract>
          <AbstractText>Retrieval of circulating tumor cells (CTC) has proven valuable for assessing a patient's cancer burden, evaluating response to therapy, and analyzing which drug might treat a cancer best. Although most isolation methods retrieve CTCs based on size, shape, or capture by tumor-specific antibodies, we explore here the use of small molecule tumor-specific ligands linked to magnetic beads for CTC capture. We have designed folic acid-biotin conjugates with different linkers for the capture of folate receptor (FR) + tumor cells spiked into whole blood, and application of the same technology to isolate FR + CTCs from the peripheral blood of both tumor-bearing mice and non-small cell lung patients. We demonstrate that folic acid linked via a rigid linker to a flexible PEG spacer that is in turn tethered to a magnetic bead enables optimal CTC retrieval, reaching nearly 100% capture when 100 cancer cells are spiked into 1 mL of aqueous buffer and ~ 90% capture when the same quantity of cells is diluted into whole blood. In a live animal model, the same methodology is shown to efficiently retrieve CTCs from tumor-bearing mice, yielding cancer cell counts that are proportional to total tumor burden. More importantly, the same method is shown to collect ~ 29 CTCs/8 mL peripheral blood from patients with non-small cell lung cancer. Since the ligand-presentation strategy optimized here should also prove useful in targeting other nanoparticles to other cells, the methods described below should have general applicability in the design of nanoparticles for cell-specific targeting.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yingwen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Danyang</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Napoleon</LastName>
            <ForeName>John V</ForeName>
            <Initials>JV</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srinivasarao</LastName>
            <ForeName>Madduri</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singhal</LastName>
            <ForeName>Sunil</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Savran</LastName>
            <ForeName>Cagri A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>School of Mechanical Engineering, Birck Nanotechnology Center, Purdue Center for Cancer Research, Purdue University, 1205 W. State St., West Lafayette, IN, 47907, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Low</LastName>
            <ForeName>Philip S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Purdue Center for Cancer Research, Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA. plow@purdue.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>935E97BOY8</RegistryNumber>
          <NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002469" MajorTopicYN="N">Cell Separation</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="Y">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>23</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35595733</ArticleId>
        <ArticleId IdType="pmc">PMC9122947</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-12118-3</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-12118-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564. doi: 10.1126/science.1203543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1203543</ArticleId>
            <ArticleId IdType="pubmed">21436443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moussavi-Harami SF, Wisinski KB, Beebe DJ. Circulating tumor cells in metastatic breast cancer: A prognostic and predictive marker. J. Patient-Centered Res. Rev. 2014;1:85–92. doi: 10.17294/2330-0698.1017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.17294/2330-0698.1017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sastre J, et al.  Circulating tumor cells in colorectal cancer: Correlation with clinical and pathological variables. Ann. Oncol. 2008;19:935–938. doi: 10.1093/annonc/mdm583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdm583</ArticleId>
            <ArticleId IdType="pubmed">18212090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Bono JS, et al.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008;14:6302–6309. doi: 10.1158/1078-0432.CCR-08-0872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0872</ArticleId>
            <ArticleId IdType="pubmed">18829513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen SJ, et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:3213–3221. doi: 10.1200/JCO.2007.15.8923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.8923</ArticleId>
            <ArticleId IdType="pubmed">18591556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krebs MG, et al.  Molecular analysis of circulating tumour cells-biology and biomarkers. Nat. Rev. Clin. Oncol. 2014;11:129–144. doi: 10.1038/nrclinonc.2013.253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2013.253</ArticleId>
            <ArticleId IdType="pubmed">24445517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Luca F, et al.  Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016;7:26107–26119. doi: 10.18632/oncotarget.8431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8431</ArticleId>
            <ArticleId IdType="pmc">PMC5041968</ArticleId>
            <ArticleId IdType="pubmed">27034166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forte VA, et al.  The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol. Med. 2016;13:19–40. doi: 10.28092/j.issn.2095-3941.2016.0007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.28092/j.issn.2095-3941.2016.0007</ArticleId>
            <ArticleId IdType="pmc">PMC4850125</ArticleId>
            <ArticleId IdType="pubmed">27144060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guibert N, et al.  Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. Lung Cancer. 2016;100:1–4. doi: 10.1016/j.lungcan.2016.07.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2016.07.021</ArticleId>
            <ArticleId IdType="pubmed">27597273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–491. doi: 10.1158/2159-8290.cd-15-1483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.cd-15-1483</ArticleId>
            <ArticleId IdType="pubmed">26969689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35:1216–1224. doi: 10.1038/onc.2015.192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.192</ArticleId>
            <ArticleId IdType="pubmed">26050619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coumans FA, Ligthart ST, Uhr JW, Terstappen LW. Challenges in the enumeration and phenotyping of CTC. Clin. Cancer Res. 2012;18:5711–5718. doi: 10.1158/1078-0432.CCR-12-1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1585</ArticleId>
            <ArticleId IdType="pubmed">23014524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer. 2008;8:329. doi: 10.1038/nrc2375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2375</ArticleId>
            <ArticleId IdType="pubmed">18404148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorges TM, et al.  Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012;12:178–178. doi: 10.1186/1471-2407-12-178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-12-178</ArticleId>
            <ArticleId IdType="pmc">PMC3502112</ArticleId>
            <ArticleId IdType="pubmed">22591372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M, Braun S. Circulating tumor cells revisited. JAMA. 2010;303:1092–1093. doi: 10.1001/jama.2010.292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2010.292</ArticleId>
            <ArticleId IdType="pubmed">20233831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thurm H, et al.  Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin. Cancer Res. 2003;9:2598–2604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12855636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lampignano, R., Schneck, H., Neumann, M., Fehm, T. &amp; Neubauer, H. in Isolation and Molecular Characterization of Circulating Tumor Cells (eds Mark Jesus M. Magbanua &amp; John W. Park) 181–203 (Springer, 2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Swennenhuis JF, van Dalum G, Zeune LL, Terstappen LWMM. Improving the cell search® system. Expert Rev. Mol. Diagn. 2016;16:1291–1305. doi: 10.1080/14737159.2016.1255144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14737159.2016.1255144</ArticleId>
            <ArticleId IdType="pubmed">27797592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. Circulating tumor cells: A review of non–EpCAM-based approaches for cell enrichment and isolation. Clin. Chem. 2016;62:571–581. doi: 10.1373/clinchem.2015.249706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2015.249706</ArticleId>
            <ArticleId IdType="pubmed">26896446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao SJ, Wan Y, Xia YQ, Zou X, Zheng SY. Size-based separation methods of circulating tumor cells. Adv Drug Deliv Rev. 2018;125:3–20. doi: 10.1016/j.addr.2018.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2018.01.002</ArticleId>
            <ArticleId IdType="pubmed">29326054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bankó P, et al.  Technologies for circulating tumor cell separation from whole blood. J. Hematol. Oncol. 2019;12:48. doi: 10.1186/s13045-019-0735-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-019-0735-4</ArticleId>
            <ArticleId IdType="pmc">PMC6518774</ArticleId>
            <ArticleId IdType="pubmed">31088479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lankiewicz S, et al.  Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell. Oncol. 2008;30:463–471. doi: 10.3233/clo-2008-0432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/clo-2008-0432</ArticleId>
            <ArticleId IdType="pmc">PMC4618564</ArticleId>
            <ArticleId IdType="pubmed">18936523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieglschmid V, et al.  Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Res. 2007;27:1823–1832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17649779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Payne RE, et al.  Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics. 2008;10:51–57. doi: 10.2217/14622416.10.1.51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/14622416.10.1.51</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winter SC, et al.  Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma. BMC Cancer. 2009;9:424–424. doi: 10.1186/1471-2407-9-424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-9-424</ArticleId>
            <ArticleId IdType="pmc">PMC3087340</ArticleId>
            <ArticleId IdType="pubmed">19961621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pestrin M, et al.  Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 2009;118:523. doi: 10.1007/s10549-009-0461-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-009-0461-7</ArticleId>
            <ArticleId IdType="pubmed">19597704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ignatiadis M, et al.  HER2-positive circulating tumor cells in breast cancer. PLoS ONE. 2011;6:e15624. doi: 10.1371/journal.pone.0015624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0015624</ArticleId>
            <ArticleId IdType="pmc">PMC3018524</ArticleId>
            <ArticleId IdType="pubmed">21264346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stathopoulou A, et al.  Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: Comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 2003;23:1883–1890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12820473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemmner W. Currently used markers for CTC isolation-advantages, limitations and impact on cancer prognosis. J. Clin. Exp. Pathol. 2011;40:1125.</Citation>
        </Reference>
        <Reference>
          <Citation>Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int. J. Gynecol. Cancer. 2011;21:822–830. doi: 10.1097/IGC.0b013e318216cb91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IGC.0b013e318216cb91</ArticleId>
            <ArticleId IdType="pubmed">21613958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J-P, et al.  MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chin. J. Cancer. 2011;30:54–61. doi: 10.5732/cjc.010.10239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5732/cjc.010.10239</ArticleId>
            <ArticleId IdType="pmc">PMC4012263</ArticleId>
            <ArticleId IdType="pubmed">21192844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makurvet FD. Biologics vs. small molecules: Drug costs and patient access. Med. Drug Discov. 2021;9:100075. doi: 10.1016/j.medidd.2020.100075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.medidd.2020.100075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chem. Rev. 2017;117:12133–12164. doi: 10.1021/acs.chemrev.7b00013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.chemrev.7b00013</ArticleId>
            <ArticleId IdType="pubmed">28898067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 2008;41:120–129. doi: 10.1021/ar7000815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ar7000815</ArticleId>
            <ArticleId IdType="pubmed">17655275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker N, et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005;338:284–293. doi: 10.1016/j.ab.2004.12.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ab.2004.12.026</ArticleId>
            <ArticleId IdType="pubmed">15745749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leamon CP, et al.  Folate-vinca alkaloid conjugates for cancer therapy: A structure-activity relationship. Bioconjug. Chem. 2014;25:560–568. doi: 10.1021/bc400441s.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bc400441s</ArticleId>
            <ArticleId IdType="pubmed">24564229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 1998;15:223. doi: 10.1615/CritRevTherDrugCarrierSyst.v15.i6.20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1615/CritRevTherDrugCarrierSyst.v15.i6.20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J. Pharm. Sci. 2005;94:2135–2146. doi: 10.1002/jps.20457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.20457</ArticleId>
            <ArticleId IdType="pubmed">16136558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stella B, et al.  Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000;89:1452–1464. doi: 10.1002/1520-6017(200011)89:11&lt;1452::AID-JPS8&gt;3.0.CO;2-P.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1520-6017(200011)89:11&lt;1452::AID-JPS8&gt;3.0.CO;2-P</ArticleId>
            <ArticleId IdType="pubmed">11015690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Wang H, Hartmann LC, Cheng J-X, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc. Natl. Acad. Sci. 2007;104:11760–11765. doi: 10.1073/pnas.0703875104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0703875104</ArticleId>
            <ArticleId IdType="pmc">PMC1913863</ArticleId>
            <ArticleId IdType="pubmed">17601776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie L, et al.  Folic acid targeting for efficient isolation and detection of ovarian cancer CTCs from human whole blood based on two-step binding strategy. ACS Appl. Mater. Interfaces. 2018;10:14055–14062. doi: 10.1021/acsami.8b02583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.8b02583</ArticleId>
            <ArticleId IdType="pubmed">29620849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, et al.  Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer. J. Thorac. Oncol. 2015;10:1163–1171. doi: 10.1097/jto.0000000000000606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/jto.0000000000000606</ArticleId>
            <ArticleId IdType="pubmed">26200270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Shannessy DJ, Davis DW, Anderes K, Somers EB. Isolation of circulating tumor cells from multiple epithelial cancers with ApoStream(®) for detecting (or Monitoring) the expression of folate receptor alpha. Biomarker Insights. 2016;11:7–18. doi: 10.4137/bmi.s35075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/bmi.s35075</ArticleId>
            <ArticleId IdType="pmc">PMC4737520</ArticleId>
            <ArticleId IdType="pubmed">26848256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lian H, Ding Z, Yuan D, Ma J, Qin J. Diagnostic value of folate receptor-positive circulating tumor cell in lung cancer: A pilot study. Chin. J. Lung Cancer. 2016;19:813–820.</Citation>
        </Reference>
        <Reference>
          <Citation>Marino FZ, Ronchi A, Accardo M, Franco R. Detection of folate receptor–positive circulating tumor cells by ligand-targeted polymerase chain reaction in non-small cell lung cancer patients. J. Thorac. Dis. 2016;8:1437. doi: 10.21037/jtd.2016.05.38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd.2016.05.38</ArticleId>
            <ArticleId IdType="pmc">PMC4958780</ArticleId>
            <ArticleId IdType="pubmed">27501215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, et al.  Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl. Oncol. 2013;6:697–702. doi: 10.1593/tlo.13535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/tlo.13535</ArticleId>
            <ArticleId IdType="pmc">PMC3890704</ArticleId>
            <ArticleId IdType="pubmed">24466372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, et al.  Folate receptor-positive circulating tumor cell detected by LT-PCR–based method as a diagnostic biomarker for non–small-cell lung cancer. J. Thorac. Oncol. 2015;10:1163–1171. doi: 10.1097/JTO.0000000000000606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0000000000000606</ArticleId>
            <ArticleId IdType="pubmed">26200270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou J, et al.  Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS ONE. 2013;8:e80458. doi: 10.1371/journal.pone.0080458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0080458</ArticleId>
            <ArticleId IdType="pmc">PMC3855610</ArticleId>
            <ArticleId IdType="pubmed">24324600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhana S, Wang Y, Huang X. Nanotechnology for enrichment and detection of circulating tumor cells. Nanomedicine. 2015;10:1973–1990. doi: 10.2217/nnm.15.32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/nnm.15.32</ArticleId>
            <ArticleId IdType="pmc">PMC4889019</ArticleId>
            <ArticleId IdType="pubmed">26139129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Wu A, Chen X. Current detection technologies for circulating tumor cells. Chem. Soc. Rev. 2017;46:2038–2056. doi: 10.1039/C6CS00803H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C6CS00803H</ArticleId>
            <ArticleId IdType="pmc">PMC5598784</ArticleId>
            <ArticleId IdType="pubmed">28393954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li F, et al.  Nondestructive capture, release, and detection of circulating tumor cells with cystamine-mediated folic acid decorated magnetic nanospheres. J Mater Chem B. 2020;8:9971–9979. doi: 10.1039/d0tb01091j.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/d0tb01091j</ArticleId>
            <ArticleId IdType="pubmed">33174893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie L, et al.  Folic acid targeting for efficient isolation and detection of ovarian cancer CTCs from human whole blood based on two-step binding strategy. ACS Appl. Mater. Interfaces. 2018;10:14055–14062. doi: 10.1021/acsami.8b02583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.8b02583</ArticleId>
            <ArticleId IdType="pubmed">29620849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today. 2005;10:1451–1458. doi: 10.1016/S1359-6446(05)03575-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1359-6446(05)03575-0</ArticleId>
            <ArticleId IdType="pubmed">16243265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlashi E, Kelderhouse LE, Sturgis JE, Low PS. Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors. ACS Nano. 2013;7:8573–8582. doi: 10.1021/nn402644g.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/nn402644g</ArticleId>
            <ArticleId IdType="pubmed">24020507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H. Molecular simulations of PEGylated biomolecules, liposomes, and nanoparticles for drug delivery applications. Pharmaceutics. 2020;12:533. doi: 10.3390/pharmaceutics12060533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics12060533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 1994;269:3198–3204. doi: 10.1016/S0021-9258(17)41848-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(17)41848-5</ArticleId>
            <ArticleId IdType="pubmed">8106354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li SC, Goto NK, Williams KA, Deber CM. Alpha-helical, but not beta-sheet, propensity of proline is determined by peptide environment. Proc. Natl. Acad. Sci. U.S.A. 1996;93:6676–6681. doi: 10.1073/pnas.93.13.6676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.13.6676</ArticleId>
            <ArticleId IdType="pmc">PMC39085</ArticleId>
            <ArticleId IdType="pubmed">8692877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nilsson I, et al.  Proline-induced disruption of a transmembrane α-helix in its natural environment. J. Mol. Biol. 1998;284:1165–1175. doi: 10.1006/jmbi.1998.2217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/jmbi.1998.2217</ArticleId>
            <ArticleId IdType="pubmed">9837734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh M, Neumaier M, Nezam R, Izbicki JR, Schumacher U. Correlation of circulating tumor cells with tumor size and metastatic load in a spontaneous lung metastasis model. Anticancer Res. 2004;24:1421–1426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15274304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin T, et al.  Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cell. Immunol. 2016;300:41–45. doi: 10.1016/j.cellimm.2015.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2015.11.009</ArticleId>
            <ArticleId IdType="pubmed">26677760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009;119:1420–1428. doi: 10.1172/JCI39104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI39104</ArticleId>
            <ArticleId IdType="pmc">PMC2689101</ArticleId>
            <ArticleId IdType="pubmed">19487818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang M-C, et al.  Clinical significance of circulating tumor microemboli as a prognostic marker in patients with pancreatic ductal adenocarcinoma. Clin. Chem. 2016;62:505–513. doi: 10.1373/clinchem.2015.248260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2015.248260</ArticleId>
            <ArticleId IdType="pubmed">26861552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, et al.  Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Cancer Cell Int. 2017;17:6. doi: 10.1186/s12935-016-0373-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-016-0373-7</ArticleId>
            <ArticleId IdType="pmc">PMC5217234</ArticleId>
            <ArticleId IdType="pubmed">28070168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marks IS, et al.  Development of a small molecule tubulysin B conjugate for treatment of carbonic anhydrase IX receptor expressing cancers. Mol Pharm. 2018;15:2289–2296. doi: 10.1021/acs.molpharmaceut.8b00139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00139</ArticleId>
            <ArticleId IdType="pubmed">29715036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy J, Kaake M, Srinivasarao M, Low PS. Targeted tubulysin B hydrazide conjugate for the treatment of luteinizing hormone-releasing hormone receptor-positive cancers. Bioconjug. Chem. 2018;29:2208–2214. doi: 10.1021/acs.bioconjchem.8b00164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.bioconjchem.8b00164</ArticleId>
            <ArticleId IdType="pubmed">29851465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanduluru AK, Srinivasarao M, Wayua C, Low PS. Evaluation of a neurokinin-1 receptor-targeted technetium-99m conjugate for neuroendocrine cancer imaging. Mol. Imag. Biol. 2020;22:377–383. doi: 10.1007/s11307-019-01391-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11307-019-01391-w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kularatne SA, Wang K, Santhapuram HK, Low PS. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 2009;6:780–789. doi: 10.1021/mp900069d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp900069d</ArticleId>
            <ArticleId IdType="pubmed">19361233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wayua C, Low PS. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers. J. Nucl. Med. 2015;56:113–119. doi: 10.2967/jnumed.114.144998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2967/jnumed.114.144998</ArticleId>
            <ArticleId IdType="pubmed">25500824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahalingam SM, Chu H, Liu X, Leamon CP, Low PS. Carbonic anhydrase IX-targeted near-infrared dye for fluorescence imaging of hypoxic tumors. Bioconjug Chem. 2018;29:3320–3331. doi: 10.1021/acs.bioconjchem.8b00509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.bioconjchem.8b00509</ArticleId>
            <ArticleId IdType="pubmed">30185025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sneddon D, et al.  Synthesis and in vivo biological evaluation of (68)Ga-labeled carbonic anhydrase IX targeting small molecules for positron emission tomography. J. Med. Chem. 2016;59:6431–6443. doi: 10.1021/acs.jmedchem.6b00623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b00623</ArticleId>
            <ArticleId IdType="pubmed">27322137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olberg DE, et al.  Synthesis and in vitro evaluation of small-molecule [18F] labeled gonadotropin-releasing hormone (GnRH) receptor antagonists as potential PET imaging agents for GnRH receptor expression. Bioorg. Med. Chem. Lett. 2014;24:1846–1850. doi: 10.1016/j.bmcl.2014.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmcl.2014.02.002</ArticleId>
            <ArticleId IdType="pubmed">24613701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, et al.  Synthesis and evaluation of a novel (64)Cu- and (67)Ga-labeled neurokinin 1 receptor antagonist for in vivo targeting of NK1R-positive tumor xenografts. Bioconjug Chem. 2018;29:1319–1326. doi: 10.1021/acs.bioconjchem.8b00063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.bioconjchem.8b00063</ArticleId>
            <ArticleId IdType="pubmed">29466853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brom M, et al.  Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors. Mol. Imaging. 2011;10:144–152. doi: 10.2310/7290.2010.00032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2310/7290.2010.00032</ArticleId>
            <ArticleId IdType="pmc">PMC3123532</ArticleId>
            <ArticleId IdType="pubmed">21439259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaughn BA, et al.  Chelation with a twist: A bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44. Chem. Sci. 2020;11:333–342. doi: 10.1039/c9sc04655k.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c9sc04655k</ArticleId>
            <ArticleId IdType="pmc">PMC7472660</ArticleId>
            <ArticleId IdType="pubmed">32953004</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
